Characterizing the outcomes of metastatic papillary renal cell carcinoma.

about

Characterizing the outcomes of metastatic papillary renal cell carcinoma.

Item

http://www.wikidata.org/entity/Q42172414

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Characterizing the outcomes of metastatic papillary renal cell carcinoma.

@en

Characterizing the outcomes of metastatic papillary renal cell carcinoma.

@nl

type

Item

label

Characterizing the outcomes of metastatic papillary renal cell carcinoma.

@en

Characterizing the outcomes of metastatic papillary renal cell carcinoma.

@nl

prefLabel

Characterizing the outcomes of metastatic papillary renal cell carcinoma.

@en

Characterizing the outcomes of metastatic papillary renal cell carcinoma.

@nl

P1476

Characterizing the outcomes of metastatic papillary renal cell carcinoma.

@en

P2093

Anna P Fraccon

http://www.w3.org/2001/XMLSchema#string

Daniel Y C Heng

http://www.w3.org/2001/XMLSchema#string

Douglas Scott Ernst

http://www.w3.org/2001/XMLSchema#string

Felice Pasini

http://www.w3.org/2001/XMLSchema#string

Georg A Bjarnason

http://www.w3.org/2001/XMLSchema#string

Isaac Alex Bowman

http://www.w3.org/2001/XMLSchema#string

Jae-Lyun Lee

http://www.w3.org/2001/XMLSchema#string

Jennifer J Knox

http://www.w3.org/2001/XMLSchema#string

Lori A Wood

http://www.w3.org/2001/XMLSchema#string

Neeraj Agarwal

http://www.w3.org/2001/XMLSchema#string

P2860

Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial.

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

Prognostic impact of histological subtype on surgically treated localized renal cell carcinoma.

Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies.

Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma.

Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology.

PD-L1 expression in nonclear-cell renal cell carcinoma.

Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma.

P304

902-909

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CAM4.1048

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-04-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28414866

http://www.w3.org/2001/XMLSchema#string

P932

5430092

http://www.w3.org/2001/XMLSchema#string